Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
329 hedge funds and large institutions have $8.76B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2022 Q2 according to their latest regulatory filings, with 109 funds opening new positions, 98 increasing their positions, 99 reducing their positions, and 81 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 10 → 30 (+20)
82% more call options, than puts
Call options by funds: $86.5M | Put options by funds: $47.5M
35% more first-time investments, than exits
New positions opened: 109 | Existing positions closed: 81
19% more capital invested
Capital invested by funds: $7.35B → $8.76B (+$1.42B)
7% more funds holding
Funds holding: 307 → 329 (+22)
1% less repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 99
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$364M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$249M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$248M |
| 4 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$183M |
| 5 |
SFM
Soros Fund Management
New York
|
+$160M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$511M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$208M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$183M |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$177M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$148M |
BHVN Hedge Fund Activity: Q2 2022 in Review
329 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q2 2022, worth a combined $8.76B — up 19% from $7.35B a quarter earlier.
Buyers outnumbered sellers: 109 funds opened new BHVN positions and 81 closed out — a net gain of 28 holders — while 98 added to existing stakes and 99 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $364M. The largest seller was Capital World Investors, cutting an estimated $511M.
- 329 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q2 2022, up from 307 in Q1 2022.
- Funds reported $8.76B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q2 2022, up 19% quarter-over-quarter.
- 109 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q2 2022 and 81 closed out, a net change of +28 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q2 2022 was Adage Capital Partners, an estimated $364M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q2 2022 was Capital World Investors, an estimated $511M sold.
Based on aggregated 13F filings for Q2 2022.